The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote competition in health care and support lower prescription drug costs. Among other things, the agencies will seek public input on the impact of private equity and corporate control in health care to identify areas for future regulation and enforcement; improve information sharing to better identify anticompetitive “rollups” that evade antitrust scrutiny; and appoint an HHS chief competition officer and health care chief counsels at DOJ and FTC. 

In addition, the Centers for Medicare & Medicaid Services today released ownership data for Federally Qualified Health Centers and Rural Health Clinics and plans to seek public input early next year to strengthen data and transparency in the Medicare Advantage market, the Administration said. The Department of Commerce and HHS also proposed a framework to promote access to taxpayer-funded inventions, including medical treatments.

Related News Articles

Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…